677 related articles for article (PubMed ID: 8862437)
1. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
2. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
3. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
4. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes.
Buckner FS; Wipke BT; Van Voorhis WC
Eur J Immunol; 1997 Oct; 27(10):2541-8. PubMed ID: 9368608
[TBL] [Abstract][Full Text] [Related]
5. [Reduced expression of class I MHC antigens in NIH3T3 cells transformed with activated ras oncogenes].
Matsushima S
Hokkaido Igaku Zasshi; 1987 Sep; 62(5):790-7. PubMed ID: 3500904
[TBL] [Abstract][Full Text] [Related]
6. Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells.
Aosai F; Ohlen C; Ljunggren HG; Höglund P; Franksson L; Ploegh H; Townsend A; Kärre K; Stauss HJ
Eur J Immunol; 1991 Nov; 21(11):2767-74. PubMed ID: 1936122
[TBL] [Abstract][Full Text] [Related]
7. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone.
Zügel U; Schoel B; Kaufmann SH
J Immunol; 1994 Nov; 153(9):4070-80. PubMed ID: 7523514
[TBL] [Abstract][Full Text] [Related]
8. Class I-restricted alloreactive cytotoxic T lymphocytes recognize a complex array of specific MHC-associated peptides.
Wang W; Man S; Gulden PH; Hunt DF; Engelhard VH
J Immunol; 1998 Feb; 160(3):1091-7. PubMed ID: 9570521
[TBL] [Abstract][Full Text] [Related]
9. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells.
Bellone M; Iezzi G; Manfredi AA; Protti MP; Dellabona P; Casorati G; Rugarli C
Eur J Immunol; 1994 Nov; 24(11):2691-8. PubMed ID: 7525300
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
Seliger B; Harders C; Lohmann S; Momburg F; Urlinger S; Tampé R; Huber C
Eur J Immunol; 1998 Jan; 28(1):122-33. PubMed ID: 9485192
[TBL] [Abstract][Full Text] [Related]
11. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
12. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes.
Flyer DC; Burakoff SJ; Faller DV
J Immunol; 1985 Oct; 135(4):2287-92. PubMed ID: 2411792
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses.
De Bruijn ML; Nieland JD; Schumacher TN; Ploegh HL; Kast WM; Melief CJ
Eur J Immunol; 1992 Nov; 22(11):3013-20. PubMed ID: 1425925
[TBL] [Abstract][Full Text] [Related]
14. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
15. The Q7 alpha 3 domain alters T cell recognition of class I antigens.
Aldrich CJ; Lowen LC; Mann D; Nishimura M; Hood L; Stroynowski I; Forman J
J Immunol; 1991 May; 146(9):3082-90. PubMed ID: 1849941
[TBL] [Abstract][Full Text] [Related]
16. Tetramer-blocking assay for defining antigen-specific cytotoxic T lymphocytes using peptide-MHC tetramer.
Yokouchi H; Chamoto K; Wakita D; Noguchi D; Yamazaki K; Dosaka-Akita H; Nishimura M; Ikeda H; Nishimura T
Cancer Sci; 2006 Feb; 97(2):148-54. PubMed ID: 16441426
[TBL] [Abstract][Full Text] [Related]
17. Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M; Pfeifer J; Stockinger B; Wick MJ
Behring Inst Mitt; 1997 Feb; (98):197-211. PubMed ID: 9382741
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line.
Sijts AJ; De Bruijn ML; Nieland JD; Kast WM; Melief CJ
Eur J Immunol; 1992 Jun; 22(6):1639-42. PubMed ID: 1601045
[TBL] [Abstract][Full Text] [Related]
19. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
20. The role of surface HLA-A,B,C molecules in tumour immunity.
Möller P; Hämmerling GJ
Cancer Surv; 1992; 13():101-27. PubMed ID: 1423320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
